Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sezary Syndrome 1Sarcoma 1Paget Disease, Extramammary 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1Mycosis Fungoides 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Eccrine Porocarcinoma 1Carcinoma, Signet Ring Cell 1Carcinoma, Merkel Cell 1Carcinoma, Basosquamous 1Carcinoma, Basal Cell 1Adenocarcinoma, Papillary 1

Interventions

Specimen Handling 3Doxorubicin 3Biopsy 3Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Gemcitabine 2toripalimab 1talimogene laherparepvec 1ribociclib 1peposertib 1pazopanib 1liposomal doxorubicin 1cabozantinib 1abemaciclib 1Temozolomide 1Surgical Procedures, Operative 1PM 01183 1Nivolumab 1Neoadjuvant Therapy 1Ifosfamide 1Everolimus 1Docetaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyosarcoma × talimogene laherparepvec × 90 days × Clear all
NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡